Type 2 Drug May Up Amputation Risk
The type 2 diabetes drug canagliflozin (Invokana) cuts the risk for heart attacks, but its label also carries a warning about an increased risk for amputations. That’s because a recent study showed that amputations occurred in about six of every 1,000 people treated with canagliflozin for a year, compared with three of every 1,000 given a placebo. A new study is challenging that. After poring over medical records of more than 700,000 people with type 2 diabetes, researchers found no increase in amputations for those taking canagliflozin compared with those taking other glucose-lowering drugs. Still, the authors say other drugs may be preferable in people who have amputation risk factors, such as poor circulation, nerve damage in the feet, or a prior amputation.
Source: The American Diabetes Association 78th annual Scientific Sessions.